Head to head
Retatrutide against MariTide
Two investigational obesity drugs with similar reported weight loss and opposite designs, a three receptor peptide dosed weekly against an antibody peptide conjugate dosed monthly that blocks one of the receptors retatrutide activates.
Column A
RetatrutideRetatrutide (triple GLP-1/GIP/glucagon agonist)
An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to date in trials.
Column B
MariTideMaridebart Cafraglutide (MariTide, AMG 133)
Amgen's monthly-dosed obesity drug that pairs GLP-1 activation with GIP receptor blockade, reaching around 20% weight loss in Phase 2.
Side by side, on the facts we can check
| Attribute | Retatrutide | MariTide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational, not FDA-approved; Phase 3 TRIUMPH-1 reported May 2026; submission expected late 2026 | Investigational (Phase 3) |
| Half-life | ~6 days | Weeks (monthly dosing) |
| Molecular weight | ~4,731 Da | About 145 kDa: the maridebart antibody component is 144,765 Da (KEGG) and carries two conjugated GLP-1 peptide analogs |
| Mechanism | Agonizes GLP-1, GIP, and glucagon receptors. The added glucagon activity increases energy expenditure and hepatic fat oxidation, complementing the appetite and insulin effects of the incretin receptors. | Activates the GLP-1 receptor while blocking the GIP receptor, delivered as a long-acting peptide-antibody conjugate for monthly dosing. |
| Human studies cited | 3 | 2 |
| Legal status, US | Investigational, not approved for any indication | Investigational, not approved |
Frequently asked questions
What is the difference between Retatrutide and MariTide?
Retatrutide: An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to date in trials. MariTide: Amgen's monthly-dosed obesity drug that pairs GLP-1 activation with GIP receptor blockade, reaching around 20% weight loss in Phase 2.
Which has stronger research evidence, Retatrutide or MariTide?
This database does not grade compounds. It counts what was run in people: 3 of the 4 studies cited on the Retatrutide profile were human work, against 2 of 2 for MariTide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Retatrutide and MariTide FDA-approved?
Retatrutide: Investigational, not FDA-approved; Phase 3 TRIUMPH-1 reported May 2026; submission expected late 2026. MariTide: Investigational (Phase 3).
Related posts
Blog articles that cover Retatrutide or MariTide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.